These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15752306)

  • 1. Livedo reticularis associated with interferon alpha therapy in two melanoma patients.
    Ruiz-Genao DP; García-F-Villalta MJ; Hernández-Núñez A; Ríos-Buceta L; Fernández-Herrera J; García-Díez A
    J Eur Acad Dermatol Venereol; 2005 Mar; 19(2):252-4. PubMed ID: 15752306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Livedo reticularis: a side effect of interferon therapy in a pediatric patient with melanoma.
    Fox M; Tahan S; Kim CC
    Pediatr Dermatol; 2012; 29(3):333-5. PubMed ID: 21575046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atrophie blanche associated with interferon-alfa adjuvant therapy for melanoma: a cutaneous side effect related to the procoagulant activity of interferon?
    Bugatti L; Filosa G; Nicolini M; Filosa A; Verdolini R
    Dermatology; 2002; 204(2):154. PubMed ID: 11937746
    [No Abstract]   [Full Text] [Related]  

  • 4. Nursing management of patients with malignant melanoma receiving adjuvant alpha interferon-2b.
    Kiley KE; Gale DM
    Clin J Oncol Nurs; 1998 Jan; 2(1):11-6. PubMed ID: 9481251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Grand mal seizure induced by interferon-alpha-2b.
    Kors C; Milling A; Hofmann M; Sterry W; Trefzer U
    J Eur Acad Dermatol Venereol; 2006 Apr; 20(4):473-4. PubMed ID: 16643159
    [No Abstract]   [Full Text] [Related]  

  • 6. Lipoatrophy associated with interferon alfa adjuvant therapy for melanoma.
    Vallés L; González M; Polo I; Enguita AB; Vanaclocha F; Ortiz-Romero PL
    Arch Dermatol; 2009 Jan; 145(1):98-9. PubMed ID: 19153363
    [No Abstract]   [Full Text] [Related]  

  • 7. Severe action tremor related to interferon-alpha 2b therapy for malignant melanoma.
    Nishihori T; Abdo-Matkiwsky M; Fleishman SB; Blum RH
    Am J Clin Oncol; 2005 Oct; 28(5):526. PubMed ID: 16199995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma.
    Guillot B; Blazquez L; Bessis D; Dereure O; Guilhou JJ
    Dermatology; 2004; 208(1):49-54. PubMed ID: 14730237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early signs of liver failure after low-dose interferon alfa-2b for cutaneous melanoma.
    Ammoury A; El Sayed F; Farah C; Bazex J
    J Am Acad Dermatol; 2008 Mar; 58(3):532-3. PubMed ID: 18280369
    [No Abstract]   [Full Text] [Related]  

  • 10. Urticaria, angioedema and dyspnoea in adjuvant therapy of melanoma with interferon alpha-2b.
    Helbig D; Simon JC; Treudler R
    Acta Derm Venereol; 2010 May; 90(3):308-9. PubMed ID: 20526557
    [No Abstract]   [Full Text] [Related]  

  • 11. [Ocular complications of adjuvant interferon therapy for malignant melanoma: a review].
    Ockenfels M; Lisch W
    Hautarzt; 2003 Feb; 54(2):144-7. PubMed ID: 12590309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
    Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
    Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interstitial pneumonitis in a patient with melanoma treated with the high dose interferon alpha 2b regimen.
    Siegelmann-Danieli N; Bardo M; Law A; Fisk D; Bernath A
    Isr Med Assoc J; 2004 Oct; 6(10):636-7. PubMed ID: 15473596
    [No Abstract]   [Full Text] [Related]  

  • 14. Impaired platelet aggregation in melanoma patients treated with interferon-alpha-2b adjuvant therapy.
    Gutman H; Schachter J; Stopel E; Gutman R; Lahav J
    Cancer; 2002 Feb; 94(3):780-5. PubMed ID: 11857313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma.
    Wong SF; Jakowatz JG; Taheri R
    Ann Pharmacother; 2004 Oct; 38(10):1655-9. PubMed ID: 15304625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma.
    Friebe A; Schwarz MJ; Schmid-Wendtner M; Volkenandt M; Schmidt F; Horn M; Janssen G; Schaefer M
    J Immunother; 2007 Apr; 30(3):333-7. PubMed ID: 17414324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined adjuvant radiation and interferon-alpha 2B therapy in high-risk melanoma patients: the potential for increased radiation toxicity.
    Hazard LJ; Sause WT; Noyes RD
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):796-800. PubMed ID: 11849803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropsychiatric complications associated with interferon - alpha -2b treatment of malignant melanoma.
    Enudi W; Udolu OJ
    Afr J Psychiatry (Johannesbg); 2009 Aug; 12(3):227-8. PubMed ID: 19750253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality-of-life evaluation in an interferon therapy after radical surgery in cutaneous melanoma patients.
    Rataj D; Jankowiak B; Krajewska-Kułak E; Van Damme-Ostapowicz K; Nowecki ZI; Rutkowski P; Niczyporuk W
    Cancer Nurs; 2005; 28(3):172-8. PubMed ID: 15915059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.
    Jonasch E; Kumar UN; Linette GP; Hodi FS; Soiffer RJ; Ryan BF; Sober AJ; Mihm MC; Tsao H; Langley RG; Cosimi BA; Gadd MA; Tanabe KK; Souba W; Haynes HA; Barnhill R; Osteen R; Haluska FG
    Cancer J; 2000; 6(3):139-45. PubMed ID: 10882328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.